Literature DB >> 9572397

High cell density induces vascular endothelial growth factor expression via protein tyrosine phosphorylation.

D Mukhopadhyay1, L Tsiokas, V P Sukhatme.   

Abstract

Expression of vascular endothelial growth factor (VEGF), an angiogenic factor and endothelial cell-specific mitogen, is induced by hypoxia in various cell lines as well as in solid tumors. In this study, we report that cell density has a profound effect on the expression of VEGF in human glioblastoma cells (U87) and human fibrosarcoma cells (HT1080), an effect that is independent of hypoxia. Northern blot analysis revealed that VEGF mRNA levels were four- to eightfold higher in cells seeded at high density compared to cells seeded at low density. This upregulation of VEGF message in response to seeding at high density was not seen with other mRNAs such as those for TGF-beta1 or GAPDH. Conditioned medium switch experiments between sparse and dense cells suggested that soluble factor(s) may not account for the observed changes in VEGF expression. Incubation with genistein, a protein tyrosine kinase inhibitor, for 3 h following seeding resulted in the reduction of the VEGF mRNA levels in highly confluent cultures but not in sparse cultures. To identify protein tyrosine kinases involved in the upregulation of the steady-state levels of VEGF mRNA in highly dense cultures, we analyzed the phosphorylation state of the c-src tyrosine kinase, in high versus low confluency cultures of U87 and HT1080 cells. Interestingly, an increased phosphorylation at Tyr416 of c-src was noted in high compared to low confluency, suggesting the activation of c-src in highly confluent cultures. Because extracellular signal-regulated kinases (ERKs) such as MAP kinase have been shown to be activated by extracellular stimuli and act downstream of c-src, we examined their possible involvement in this process. We found that the tyrosine phosphorylation level of MAP kinase is higher in dense compared to sparse cultures and, moreover, 6-thioguanine (6-TG), a potent inhibitor of ERKs, reduced VEGF mRNA levels in high but not low confluency. Furthermore, reintroduction of wild-type, but not mutant, von Hippel-Lindau (VHL) gene product in 786-O cells (a renal carcinoma cell line) specifically abrogated the induction of VEGF mRNA due to high cell density. Taken together, these data suggest that VEGF gene expression is regulated by cell density, and the protooncogene c-src and the tumor-suppressor VHL are modulators of this regulation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9572397      PMCID: PMC6151943     

Source DB:  PubMed          Journal:  Gene Expr        ISSN: 1052-2166


  27 in total

Review 1.  Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation.

Authors:  L A Liotta; P S Steeg; W G Stetler-Stevenson
Journal:  Cell       Date:  1991-01-25       Impact factor: 41.582

2.  Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors.

Authors:  B Berse; L F Brown; L Van de Water; H F Dvorak; D R Senger
Journal:  Mol Biol Cell       Date:  1992-02       Impact factor: 4.138

3.  Clinical features and natural history of von Hippel-Lindau disease.

Authors:  E R Maher; J R Yates; R Harries; C Benjamin; R Harris; A T Moore; M A Ferguson-Smith
Journal:  Q J Med       Date:  1990-11

4.  Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma.

Authors:  N Weidner; P R Carroll; J Flax; W Blumenfeld; J Folkman
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

5.  Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation.

Authors:  D Mukhopadhyay; L Tsiokas; X M Zhou; D Foster; J S Brugge; V P Sukhatme
Journal:  Nature       Date:  1995-06-15       Impact factor: 49.962

6.  Identification of the von Hippel-Lindau disease tumor suppressor gene.

Authors:  F Latif; K Tory; J Gnarra; M Yao; F M Duh; M L Orcutt; T Stackhouse; I Kuzmin; W Modi; L Geil
Journal:  Science       Date:  1993-05-28       Impact factor: 47.728

7.  Suppression of growth of renal carcinoma cells by the von Hippel-Lindau tumor suppressor gene.

Authors:  F Chen; T Kishida; F M Duh; P Renbaum; M L Orcutt; L Schmidt; B Zbar
Journal:  Cancer Res       Date:  1995-11-01       Impact factor: 12.701

8.  Mutations of the VHL tumour suppressor gene in renal carcinoma.

Authors:  J R Gnarra; K Tory; Y Weng; L Schmidt; M H Wei; H Li; F Latif; S Liu; F Chen; F M Duh
Journal:  Nat Genet       Date:  1994-05       Impact factor: 38.330

9.  Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C.

Authors:  A Kibel; O Iliopoulos; J A DeCaprio; W G Kaelin
Journal:  Science       Date:  1995-09-08       Impact factor: 47.728

10.  Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas.

Authors:  S Wizigmann-Voos; G Breier; W Risau; K H Plate
Journal:  Cancer Res       Date:  1995-03-15       Impact factor: 12.701

View more
  1 in total

1.  Expression of von Hippel-Lindau tumor suppressor and tumor-associated carbonic anhydrases IX and XII in normal and neoplastic colorectal mucosa.

Authors:  Antti-J Kivela; Seppo Parkkila; Juha Saarnio; Tuomo-J Karttunen; Jyrki Kivela; Anna-Kaisa Parkkila; Maria Bartosova; Vojtech Mucha; Michal Novak; Abdul Waheed; William-S Sly; Hannu Rajaniemi; Silvia Pastorekova; Jaromir Pastorek
Journal:  World J Gastroenterol       Date:  2005-05-07       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.